Olon Expands On Multiple Fronts
Adds To HPAPI Capabilities In India And Sets Out Investment Plans In Italy
Italian API and CDMO specialist Olon is expanding its high-potency capabilities at a site in India, at the same time as unveiling plans to invest a further €30m in a domestic biotech hub.
You may also be interested in...
Italy’s Olon has opened its new R&D hub in Milan, shortly after announcing plans to expand a key manufacturing facility in India.
API specialist Olon has announced the expansion of its pipeline with the addition of two products: pralsetinib and trilaciclib.
Italian active pharmaceutical ingredient (API) supplier and contract development and manufacturing organisation (CDMO) Olon has expanded its global footprint by striking a deal to buy an API facility in Mahad, India, from Novartis. Describing the plant as “established and reputable”, Olon noted that it “provides a number of lifesaving medicines to the Indian healthcare system and patients around the world”.